BioMed Realty Trust, Inc. (BMR) Misses Q3 FFO by 1c; Narrows FY11 Outlook, Guides FY12 FFO
BioMed Realty Trust, Inc. (NYSE: BMR) reported Q3 FFO of $0.29, $0.01 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $115 million versus the consensus estimate of $109.1 million.
Aees FY2012 FFO of $1.23-$1.33, versus the consensus of $1.28.
BioMed Realty Trust, Inc. sees FY2011 FFO of $1.17-$1.19, versus the consensus of $1.19.
Aees FY2012 FFO of $1.23-$1.33, versus the consensus of $1.28.
BioMed Realty Trust, Inc. sees FY2011 FFO of $1.17-$1.19, versus the consensus of $1.19.